Prosecution Insights
Last updated: November 04, 2026

Hepgene Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Hepgene Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a highly focused prosecution effort. HANEY, AMANDA MARIE is the busiest examiner for this portfolio, overseeing 1 pending office action. The outcome of the company's current patent filing is therefore entirely dependent on the examination practices and decisions of this specific individual.

The involvement of 1 distinct art unit suggests that the technology is categorized within a specialized administrative group of Biotechnology & Pharmaceuticals. For the practitioner, this means that prosecution strategy must be tailored to the specific norms and prior art search patterns of that unit. Since HANEY, AMANDA MARIE is the only examiner currently handling a pending matter for Hepgene Inc., their historical data regarding allowance rates and interview receptivity will be the most important factor in the prosecution process.

With 1 pending office action, there is no opportunity to compare different examiner responses or art unit efficiencies within the current portfolio. The practitioner should focus on building a clear record with the assigned examiner to resolve the 1 pending office action. Because the portfolio is concentrated in a single art unit, understanding the specific preferences of that group is essential for advancing the patent objectives of Hepgene Inc.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HANEY, AMANDA MARIE 1 36.5% +45.2%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18176124 mRNA BIOMARKERS FOR DIAGNOSIS OF LIVER DISEASE HANEY, AMANDA MARIE —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18176124 mRNA BIOMARKERS FOR DIAGNOSIS OF LIVER DISEASE HANEY, AMANDA MARIE —

Top Art Units

Art UnitApps
1682 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18176124 mRNA BIOMARKERS FOR DIAGNOSIS OF LIVER DISEASE HANEY, AMANDA MARIE 1682 §101§102§103§112 Non-Final OA — Pending Feb 28, 2023

Managing Hepgene Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Hepgene Inc. have?

Hepgene Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Hepgene Inc. applications?

Amanda Marie Haney has the most, with 1 of Hepgene Inc.'s pending office actions.

What technology area are Hepgene Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month